Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 686

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 2
Chunk 686
---
 results of another public company that is
either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition
period exemptions because of the potential differences in accounting standards used.

In
addition, we intend to rely on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions
set forth in the JOBS Act and compliance with applicable laws, if, as an emerging growth company, we rely on such exemptions, we are
not required to, among other things: (a) provide an auditor’s attestation report on our system of internal control over financial
reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002; (b) provide all of the compensation disclosures that may be required
of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010; (c) comply with
any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement
to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis);
and (d) disclose certain executive compensation-related items such as the correlation between executive compensation and performance
and comparisons of the Chief Executive Officer’s compensation to median employee compensation.

We
will remain an emerging growth company under the JOBS Act until the earliest of (a) December 31, 2027, (b) the last date of our fiscal
year in which we had total annual gross revenue of at least $1.07 billion, (c) the date on which we are deemed to be a “large accelerated
filer” under the rules of the SEC or (d) the date on which we have issued more than $1.0 billion in non-convertible debt securities
during the previous three years.

Item
7A. Quantitative and Qualitative Disclosures About Market Risk.

Smaller
reporting companies are not required to provide the information required by this item.

Item
8. Financial Statements and Supplementary Data.

Our
Financial Statements and Notes thereto and the reports of Salberg & Company P.A for year ended December 31, 2024 and Chery
Bekaert for the year ended December 31, 2023, our independent registered public accounting firms, for the respective years ended
listed above, are set forth on pages F-1 through F-16 of this Report.

Item